C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Acquires 17,983 Shares of Pfizer Inc. $PFE

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 150.5% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 29,929 shares of the biopharmaceutical company’s stock after purchasing an additional 17,983 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors’ holdings in Pfizer were worth $745,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in the stock. State Street Corp raised its holdings in shares of Pfizer by 0.9% in the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after purchasing an additional 2,786,098 shares during the period. Northern Trust Corp raised its stake in Pfizer by 1.4% in the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after acquiring an additional 869,175 shares during the period. Fisher Asset Management LLC lifted its holdings in Pfizer by 1.9% during the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after purchasing an additional 897,786 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Pfizer by 8.6% during the 3rd quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock valued at $1,063,565,000 after buying an additional 3,296,415 shares in the last quarter. Finally, Amundi boosted its holdings in Pfizer by 10.8% in the 3rd quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock worth $1,096,380,000 after buying an additional 4,043,413 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on PFE shares. TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Morgan Stanley set a $27.00 price target on Pfizer and gave the company a “positive” rating in a research report on Tuesday, March 17th. Guggenheim lifted their price target on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Barclays began coverage on Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective on the stock. Finally, Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.19.

Pfizer Price Performance

PFE opened at $28.37 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock’s 50 day simple moving average is $27.09 and its 200 day simple moving average is $25.83. The firm has a market cap of $161.29 billion, a price-to-earnings ratio of 20.86 and a beta of 0.43. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.63 earnings per share. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.